KLK3 and prostate carcinoma: The CAP trial in the United Kingdom (UK) examined prostate cancer screening in over 400,000 men who underwent a single PSA test ± biopsy when raised and found no significant difference in prostate cancer mortality between those who underwent PSA screening and the control arm at 10 years [13].